The approval of epcoritamab may impact treatment options in the R/R follicular lymphoma space, according to Tycel Phillips, MD.
Approval Alert | Epcoritamab in Relapsed/Refractory Follicular Lymphoma
The approval for epcoritamab in patients with R/R follicular lymphoma was supported by encouraging efficacy findings from the phase 1/2 EPCORE NHL-1 trial.
Bispecific antibodies including epcoritamab have “a lot of potential for upward mobility” in lymphoma, according to Tycel Phillips, MD.
Findings from the EPCORE NHL-1 trial support the FDA approval of epcoritamab in relapsed/refractory follicular lymphoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer
2
Nivolumab/Ipilimumab Improves Real-World Melanoma Outcomes Vs Pembrolizumab
3
Novel Anti-CD5 Therapy Earns FDA RMAT Designation in T-Cell Lymphoma
4
Novel T Cell Therapies Yield Decade-Long Remission in Epithelial Cancer
5
